12 minutes to Read
While metformin remains the preferred first-line pharmacological treatment for type 2 diabetes, empagliflozin and dulaglutide may replace sulphonylureas as second-line agents
Diabetes clinical nurse specialist
Lisa Sparks discusses the place of empagliflozin and dulaglutide in treatment of type 2 diabetes, with emphasis on potential side effects, sick-day management and improving patient adherence
Type 2 diabetes affects a large number of New Zealanders. According to national dispensing data, about 220,000 people aged ≥ 25 received oral hypoglycaemic agents and/or insulin between October 2019 and September 2020.
1
Generally, type 2 diabetes begins with a degree of insulin resistance but, over time, becomes a disease of insulin deficiency due to progressive pancreatic beta cell exhaustion. Metabolic, inflammatory and oxidative processes as well as glucose toxicity, lipotoxicity and hereditary factors underlie the disease pathogenesis.
Monday, 8 March 2021, 2:03 pm
Health and Disability Commissioner Morag McDowell today
released a report finding a general practitioner (GP) in
breach of the Code of Health and Disability Services
Consumers’ Rights (the Code) for failures in the care of a
woman who presented with a respiratory complaint.
The
woman, aged in her sixties at the time of events, had a
history of asthma. She saw her GP after becoming unwell with
symptoms of a tight chest, sore throat, and upset
stomach.
The GP prescribed the woman with prednisone,
a steroid medication, at a dosage of 80mg a day for a week,
Source:Â Health and Disability Commissioner
Health and Disability Commissioner Morag McDowell today released a report finding a general practitioner (GP) in breach of the Code of Health and Disability Services Consumersâ Rights (the Code) for failures in the care of a woman who presented with a respiratory complaint.
The woman, aged in her sixties at the time of events, had a history of asthma. She saw her GP after becoming unwell with symptoms of a tight chest, sore throat, and upset stomach.
The GP prescribed the woman with prednisone, a steroid medication, at a dosage of 80mg a day for a week, to be reduced to 40mg a day for another week. However, the woman remained unwell, and the GP extended the length of time she was to take the medication. Following this consultation, the woman began taking 100mg of prednisone a day, believing this to be the GPâs instruction. However, the GP stated that this was not his instruction. The GP saw the woman again after having been t
Press Release – New Zealand Formula 5000 Association
Michael Collins leads the SAS Autoparts MSC NZ F5000 Tasman Cup Revival Series field out of the hairpin at the 31st annual Skope Classic historic motor racing meeting at Mike Pero Motorsport Park – Ruapuna
Local ace Michael Collins (Leda GM1) got within 0.168 of a second of claiming a qualifying/race win/quickest race lap clean sweep at the latest round of New Zealand’s SAS Autoparts MSC NZ F5000 Tasman Cup Revival Series in Christchurch over the weekend.
However, rather than rue the difference between himself in second place and the winner of the category’s new ‘rolling-start-handicap’ race on Sunday morning, Shayne Windelburn (Lola T400), defending category holder and current class pacesetter Collins said that he would simply have to work even harder next time.
Press Release – New Zealand Formula 5000 Association
Legendary Kiwi racing driver & car builder Graham McRae delivering his driving master class at Wigram in 1972 in his then new Leda GM1 001.
The year 1972 will go down in the annals of New Zealand’s motor racing history as the year driver/engineer Graham McRae came of age – in a car – the garish fluro pink Leda LT27/GM1 – of his own design.
This weekend, at the 31st annual Skope Classic historic motor racing meeting in Christchurch, the legacy of this great Kiwi and the very same car will be brought back to life in the SAS Autoparts MSC NZ F5000 Tasman Cup Revival Series races by category young gun Michael Collins.